Fundraising Fox

Delcath Systems

NASDAQ: DCTH

Ny, US · Founded 1987 · Delaware corporation · 151 employees on LinkedIn · 1 known investors

Find your way into Delcath Systems

Delcath Systems is a commercial-stage interventional oncology company developing minimally-invasive treatments for patients with primary and metastatic liver cancers. Its FDA-approved therapy targets adult patients with metastatic uveal melanoma, marketed in the US and Europe.

BiotechHealthtechMedical Devices

Founders & leadership

BK
Barbra KeckinChief Financial Officer2017–2020
JS
Jennifer SimpsoninPresident and CEO2015–2020
GM
Gerard MichelinChief Executive Officer
MT
Marco TagliettiNamed on SEC filing

Board

RS
Roger StollBoard director
WR
William RueckertBoard director

Investors · 1

Altium CapitalreportedNew York

Reported raises · per SEC filings

Form D private placements

$71.9M disclosed across 7 of 8 rounds · 1900–2024

▶$7MraisedMar 2024 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven SalamonDirector
  • Elizabeth CzerepakDirector
  • Vojo VukovicExecutive Officer
  • Gerard MichelExecutive Officer, Director
  • Gilad AharonDirector
  • Roger G. StollDirector
  • Martha RookExecutive Officer
  • David J. HoffmanExecutive Officer
  • Kevin MuirExecutive Officer
  • John R. SylvesterDirector
  • Sandra PennellExecutive Officer
Offering amount
$7M
Amount sold
$7M
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedMar 2023 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gerard MichelExecutive Officer, Director
  • Kevin MuirExecutive Officer
  • Anthony DiasExecutive Officer
  • John PurpuraExecutive Officer
  • Elizabeth CzerepakDirector
  • Gilad AharonDirector
  • Johnny JohnExecutive Officer
  • Steven SalamonDirector
  • David HoffmanExecutive Officer
  • Roger G. StollDirector
  • John R. SylvesterDirector
Offering amount
$25M
Amount sold
$25M
Sales commissions
$1.5M
Placement agents
Canaccord Genuity LLC, Roth Capital Partners, LLC, BTIG, LLC
First sale
Mar 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.8MraisedDec 2022 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin MuirExecutive Officer
  • Gilad AharonDirector
  • David HoffmanExecutive Officer
  • John R. SylvesterDirector
  • Roger G. StollDirector
  • Anthony DiasExecutive Officer
  • Gerard MichelExecutive Officer, Director
  • Johnny JohnExecutive Officer
  • Steven SalamonDirector
  • John PurpuraExecutive Officer
  • Elizabeth CzerepakDirector
Offering amount
$3.8M
Amount sold
$3.8M
First sale
Dec 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJul 2022 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Johnny JohnExecutive Officer
  • Steven SalamonDirector
  • Gerard MichelExecutive Officer, Director
  • Gilad AharonDirector
  • John R. SylvesterDirector
  • Elizabeth CzerepakDirector
  • Roger G. StollDirector
  • Anthony DiasExecutive Officer
  • David HoffmanExecutive Officer
  • John PurpuraExecutive Officer
  • Kevin MuirExecutive Officer
Offering amount
$5M
Amount sold
$5M
First sale
Jul 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.5MraisedAug 2019 · 33 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John R SylvesterDirector
  • Jennifer K SimpsonExecutive Officer, Director
  • Barbra C KeckExecutive Officer
  • John PurpuraExecutive Officer
  • William D RueckertDirector
  • Roger G StollDirector
  • Marco TagliettiDirector
Offering amount
$9.5M
Amount sold
$9.5M
Sales commissions
$738.3K
Placement agents
Roth Capital Partners, LLC
First sale
Aug 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedJul 2019 · 31 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Marco TagliettiDirector
  • Roger G StollDirector
  • Jennifer K SimpsonExecutive Officer, Director
  • Barbra C KeckExecutive Officer
  • John PurpuraExecutive Officer
  • William D RueckertDirector
Offering amount
$20M
Amount sold
$20M
Sales commissions
$1.4M
Proceeds to insiders
$500K
Placement agents
Roth Capital Partners, LLC
First sale
Jul 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedAug 2018 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Roger StollDirector
  • Barbra KeckExecutive Officer
  • Jennifer SimpsonExecutive Officer, Director
  • William RueckertDirector
  • Marco TagliettiDirector
Offering amount
$1.6M
Amount sold
$1.6M
Minimum investment
$1M
Sales commissions
$208K
Placement agents
Roth Capital Partners, Advisory Group Equity Services Ltd.
First sale
Jul 2018
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Delcath Systems to Attend 2 Investor Conferences | DCTH Stock Newsstocktitan.net · Aug 2026Delcath Systems (DCTH) Climbs +40% on Strong Q2 Results and Raised Guidancetickeron.com · Aug 2026Delcath Systems Inc (DCTH) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% as HEPZATO KIT Drives Growth and Guidance Raisedgurufocus.com · Aug 2026Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Whyfinance.yahoo.com · Aug 2026Delcath raises 2026 revenue guidance to $104M-$108M amid plans for 37 active centers by year-end (NASDAQ:DCTH) | Seeking Alphaseekingalpha.com · Aug 2026Delcath Systems raises 2026 revenue guidance | DCTH 8-K Filingstocktitan.net · Aug 2026

Frequently asked questions

What does Delcath Systems do?
Delcath Systems is a commercial-stage interventional oncology company developing minimally-invasive treatments for patients with primary and metastatic liver cancers. Its FDA-approved therapy targets adult patients with metastatic uveal melanoma, marketed in the US and Europe.
Who are Delcath Systems's investors?
Delcath Systems's investors include Altium Capital.
How much funding has Delcath Systems raised?
Delcath Systems has disclosed $71.9M raised across 7 of its 8 known rounds.
Where is Delcath Systems headquartered?
Delcath Systems is headquartered in Ny, US.